Imunon マネジメント

マネジメント基準チェック /34

Imunonの CEO はStacy Lindborgで、 May2024年に任命され、の在任期間は 1 年未満です。は、会社の株式の1.82%を直接所有しており、その価値は€ 205.02K 。経営陣と取締役会の平均在任期間はそれぞれ0.9年と6.3年です。

主要情報

Stacy Lindborg

最高経営責任者

US$44.1k

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	1.8%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	6.3yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Stacy Lindborg (54 yo)

less than a year

在職期間

US$44,095

報酬

Dr. Stacy R. Lindborg, Ph D., was Co-Chief Executive Officer of Brainstorm Cell Therapeutics Inc. since January 2023 until May 09, 2024 and serves as its Director since May 09, 2024. Dr. Lindborg joined th...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Michael Tardugno	Executive Chairman	17.8yrs	データなし	2.44% € 274.2k
Stacy Lindborg	President	less than a year	US$44.10k	1.82% € 205.0k
Khursheed Anwer	Executive VP & Chief Scientific Officer	10.4yrs	US$680.16k	0.020% € 2.2k
David Gaiero	CFO & Corporate Secretary	less than a year	データなし	データなし
Timothy Tumminello	Chief Accounting Officer & Controller	14.8yrs	US$137.75k	データなし
Susan Eylward	General Counsel & Corporate Secretary	less than a year	データなし	データなし
Sebastien Hazard	Executive VP & Chief Medical Officer	less than a year	データなし	0.14% € 15.5k

0.9yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: CBOの経営陣は経験豊富とはみなされません ( 0.9年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Michael Tardugno	Executive Chairman	17.8yrs	データなし	2.44% € 274.2k
Stacy Lindborg	President	3.4yrs	US$44.10k	1.82% € 205.0k
Donald Braun	Independent Director	8.9yrs	US$72.90k	0.0041% € 463.7
Wafik El-Deiry	Member of Advisory Board	no data	データなし	データなし
David Cheresh	Member of Advisory Board	no data	データなし	データなし
Michael Weinblatt	Member of Advisory Board	no data	データなし	データなし
James Dentzer	Independent Director	2.2yrs	US$61.20k	0% € 0
Frederick Fritz	Independent Director	13.3yrs	US$106.20k	0.081% € 9.1k
Jerry Glickson	Member of Advisory Board	no data	データなし	データなし
Mark Dewhirst	Member of Advisory Board	no data	データなし	データなし
Peter Corry	Member of Advisory Board	no data	データなし	データなし
Britt Glaunsinger	Member of the Advisory Board	3.8yrs	データなし	データなし

6.3yrs

平均在職期間

73yo

平均年齢

経験豊富なボード: CBOの取締役会は経験豊富であると考えられます ( 6.3年の平均在任期間)。

Imunon マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Recent updates

Imunon, Inc. Announces Results from its End-Of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

New major risk - Financial position

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New major risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

New major risk - Share price stability

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Full year 2022 earnings released: US$5.03 loss per share (vs US$3.83 loss in FY 2021)

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Third quarter 2022 earnings released: US$0.87 loss per share (vs US$0.94 loss in 3Q 2021)

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

First half 2022 earnings released: US$2.86 loss per share (vs US$4.26 loss in 1H 2021)

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings released: US$1.82 loss per share (vs US$1.29 loss in 1Q 2021)

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Full year 2021 earnings released: US$3.83 loss per share (vs US$10.08 loss in FY 2020)

Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Celsion Corporation announced that it expects to receive $28.5 million in funding

Third quarter 2021 earnings released: US$0.063 loss per share (vs US$0.24 loss in 3Q 2020)

Celsion Corporation Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform

First half 2021 earnings released: US$0.15 loss per share (vs US$0.37 loss in 1H 2020)

Celsion Corporation Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer

Celsion Corporation(NasdaqCM:CLSN) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: US$0.086 loss per share (vs US$0.20 loss in 1Q 2020)

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.77 loss in FY 2019)

Celsion Corporation Announces Update on Phase I/II Ovation 2 Study

Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores

マネジメント基準チェック /34